$XOMA
XOMA Royalty Corp

2021 Q4 Form 10-K Financial Statement

#000155837022003022 Filed on March 08, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $35.95M $38.16M $27.58M
YoY Change 30.33% 29.86% 6435.55%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.538M $20.46M $3.670M
YoY Change 50.9% 21.79% -14.45%
% of Gross Profit
Research & Development $42.00K $171.0K $40.00K
YoY Change 5.0% 0.59% -69.23%
% of Gross Profit
Depreciation & Amortization $1.000K $7.000K $0.00
YoY Change -65.0% -100.0%
% of Gross Profit
Operating Expenses $5.580M $20.63M $3.708M
YoY Change 50.49% 21.58% -16.17%
Operating Profit $17.53M $23.87M
YoY Change 41.18% -696.65%
Interest Expense -$430.0K -$1.345M -$1.240M
YoY Change -65.32% 62.05% 58.97%
% of Operating Profit -7.67% -5.19%
Other Income/Expense, Net $0.00 -$879.0K -$1.181M
YoY Change -100.0% -171.76% 269.06%
Pretax Income $29.94M $15.90M $22.69M
YoY Change 31.92% 34.75% -625.13%
Income Tax $91.00K $91.00K $25.00K
% Of Pretax Income 0.3% 0.57% 0.11%
Net Earnings $29.84M $15.80M $22.67M
YoY Change 31.67% 18.8% -624.55%
Net Earnings / Revenue 83.03% 41.4% 82.18%
Basic Earnings Per Share $0.69 $1.40
Diluted Earnings Per Share $1.999M $0.65 $1.32
COMMON SHARES
Basic Shares Outstanding 11.31M 11.29M 11.02M
Diluted Shares Outstanding 12.19M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $94.10M $94.10M $84.20M
YoY Change 11.76% 11.76% 48.5%
Cash & Equivalents $93.33M $86.36M
Short-Term Investments $774.0K $774.0K
Other Short-Term Assets $2.662M $2.662M $2.000M
YoY Change 33.1% 33.1% 400.0%
Inventory
Prepaid Expenses
Receivables $209.0K $209.0K $300.0K
Other Receivables $0.00 $0.00 $1.500M
Total Short-Term Assets $96.97M $96.97M $88.07M
YoY Change 10.12% 10.07% 46.84%
LONG-TERM ASSETS
Property, Plant & Equipment $13.00K $213.0K $21.00K
YoY Change -38.1% -46.75% -38.24%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00 $1.700M
YoY Change -100.0% -100.0% 142.86%
Other Assets $301.0K $301.0K $41.00K
YoY Change 634.15% -49.83% -72.85%
Total Long-Term Assets $69.59M $69.59M $37.22M
YoY Change 86.97% 87.07% 4.11%
TOTAL ASSETS
Total Short-Term Assets $96.97M $96.97M $88.07M
Total Long-Term Assets $69.59M $69.59M $37.22M
Total Assets $166.6M $166.6M $125.3M
YoY Change 32.95% 32.93% 30.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.072M $1.072M $456.0K
YoY Change 135.09% 114.4% -25.73%
Accrued Expenses $720.0K $720.0K $800.0K
YoY Change -10.0% -10.0% -27.27%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $8.088M
YoY Change -100.0% -100.0% 56.02%
Total Short-Term Liabilities $12.97M $12.97M $12.30M
YoY Change 5.41% 5.42% 38.61%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $12.76M
YoY Change -100.0% -100.0% -52.89%
Other Long-Term Liabilities $11.72M $11.72M $50.00K
YoY Change 23338.0% -15.08% 16.28%
Total Long-Term Liabilities $11.72M $11.72M $12.81M
YoY Change -8.55% -55.94% -52.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.97M $12.97M $12.30M
Total Long-Term Liabilities $11.72M $11.72M $12.81M
Total Liabilities $24.69M $24.69M $38.86M
YoY Change -36.48% -36.54% -24.89%
SHAREHOLDERS EQUITY
Retained Earnings -$1.165B -$1.181B
YoY Change -1.34% -1.11%
Common Stock $85.00K $84.00K
YoY Change 1.19% 15.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $141.9M $141.9M $86.42M
YoY Change
Total Liabilities & Shareholders Equity $166.6M $166.6M $125.3M
YoY Change 32.95% 32.93% 30.88%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income $29.84M $15.80M $22.67M
YoY Change 31.67% 18.8% -624.55%
Depreciation, Depletion And Amortization $1.000K $7.000K $0.00
YoY Change -65.0% -100.0%
Cash From Operating Activities $30.64M $22.68M $17.68M
YoY Change 73.31% 124.71% -526.02%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$6.000M -$26.50M -$200.0K
YoY Change 2900.0% 13150.0%
Cash From Investing Activities -$6.000M -$26.50M -$200.0K
YoY Change 2900.0% 12579.43%
FINANCING ACTIVITIES
Cash Dividend Paid $3.499M
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.439M 12.84M 23.16M
YoY Change -106.21% -35.15% 9.82%
NET CHANGE
Cash From Operating Activities 30.64M 22.68M 17.68M
Cash From Investing Activities -6.000M -26.50M -200.0K
Cash From Financing Activities -1.439M 12.84M 23.16M
Net Change In Cash 23.20M 9.013M 40.64M
YoY Change -42.91% -69.63% 139.91%
FREE CASH FLOW
Cash From Operating Activities $30.64M $22.68M $17.68M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow $30.64M $22.68M $17.68M
YoY Change 73.31% 124.91% -526.02%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0000791908
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11228792
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11315263
CY2021 us-gaap Net Income Loss
NetIncomeLoss
15798000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
13298000
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2021Q4 xoma Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
525000
CY2020Q4 xoma Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
642000
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.65
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
195000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
179000
CY2021Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
1641000
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2020Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
1452000
CY2020Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
1410000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
8088000
CY2021Q4 xoma Accrued Preferred Stock Dividend Current
AccruedPreferredStockDividendCurrent
1368000
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2021 dei Entity File Number
EntityFileNumber
001-39801
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
41000
CY2021Q4 us-gaap Assets
Assets
166562000
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
91000
CY2021Q4 xoma Contingent Consideration Under Purchase Agreements
ContingentConsiderationUnderPurchaseAgreements
8075000
CY2021 dei Entity Registrant Name
EntityRegistrantName
XOMA CORPORATION
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-2154066
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
2200 Powell Street
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 310
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Emeryville
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94608
CY2021 dei City Area Code
CityAreaCode
510
CY2021 dei Local Phone Number
LocalPhoneNumber
204-7200
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
240018070
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11319124
CY2021 dei Auditor Firm
AuditorFirmId
34
CY2021 dei Auditor Name
AuditorName
DELOITTE & TOUCHE LLP
CY2021 dei Auditor Location
AuditorLocation
San Francisco, California
CY2021Q4 us-gaap Cash
Cash
93328000
CY2020Q4 us-gaap Cash
Cash
84222000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
2049000
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1611000
CY2021Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
774000
CY2021Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
209000
CY2020Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
263000
CY2020Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
1526000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
613000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
443000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
96973000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
88065000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
531000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
200000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
359000
CY2021Q4 xoma Long Term Rights Receivable Non Current
LongTermRightsReceivableNonCurrent
69075000
CY2020Q4 xoma Long Term Rights Receivable Non Current
LongTermRightsReceivableNonCurrent
34575000
CY2020Q4 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
1693000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
301000
CY2020Q4 us-gaap Assets
Assets
125285000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1072000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
456000
CY2020Q4 xoma Contingent Consideration Under Purchase Agreements
ContingentConsiderationUnderPurchaseAgreements
75000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12967000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12302000
CY2021Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
11685000
CY2020 us-gaap Interest Expense Debt
InterestExpenseDebt
1844000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-300000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
11797000
CY2020Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
13516000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
12764000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
34000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
229000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
50000
CY2021Q4 us-gaap Liabilities
Liabilities
24686000
CY2020Q4 us-gaap Liabilities
Liabilities
38861000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.05
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.05
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0075
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0075
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
277333332
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
277333332
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11315263
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11228792
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
85000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
84000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1307030000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1267377000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1165288000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1181086000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
141876000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
86424000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
166562000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
125285000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36518000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27941000
CY2021 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
1642000
CY2020 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
1444000
CY2021 us-gaap Revenues
Revenues
38160000
CY2020 us-gaap Revenues
Revenues
29385000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
171000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
170000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20460000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16799000
CY2021 us-gaap Operating Expenses
OperatingExpenses
20631000
CY2020 us-gaap Operating Expenses
OperatingExpenses
16969000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
17529000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
12416000
CY2021 us-gaap Interest Expense Debt
InterestExpenseDebt
461000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-879000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1225000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
15889000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
91000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1501000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
15798000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
13298000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
7787000
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.78
CY2020 us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
1012000
CY2021 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-54000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11288000
CY2020 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-2670000
CY2021 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-1526000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10674000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12192000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11503000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
8793000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
7968000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
9010000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.69
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.82
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.65
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
86424000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
37140000
CY2021 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
4867000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6195000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1053000
CY2021 xoma Stock Issued During Period Value Employee Benefit Plan And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan
133000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
15798000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
141876000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
43988000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
22621000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3961000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2407000
CY2020 xoma Stock Issued During Period Value Employee Benefit Plan And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan
136000
CY2020 xoma Adjustments To Additional Paid In Capital Disgorgement
AdjustmentsToAdditionalPaidInCapitalDisgorgement
13000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
13298000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
86424000
CY2021 us-gaap Profit Loss
ProfitLoss
15798000
CY2020 us-gaap Profit Loss
ProfitLoss
13298000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
6195000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
3961000
CY2021 xoma Defined Contribution Plan Issuance Of Common Stock For Services Or Claims
DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims
90000
CY2020 xoma Defined Contribution Plan Issuance Of Common Stock For Services Or Claims
DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims
88000
CY2021 us-gaap Depreciation Nonproduction
DepreciationNonproduction
7000
CY2020 us-gaap Depreciation Nonproduction
DepreciationNonproduction
22000
CY2021 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
200000
CY2020 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
698000
CY2020 xoma Milestone Payment Non Cash Portion
MilestonePaymentNonCashPortion
7300000
CY2021 xoma Reduction Of Contingent Refund Liability
ReductionOfContingentRefundLiability
105000
CY2021 xoma Operating Lease Payments Non Cash
OperatingLeasePaymentsNonCash
-160000
CY2020 xoma Operating Lease Payments Non Cash
OperatingLeasePaymentsNonCash
-150000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-300000
CY2021 us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
-919000
CY2020 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
1526000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
765000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-542000
CY2021 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
91000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-179000
CY2020 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-163000
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1642000
CY2021 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-27000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
169000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-83000
CY2020 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1444000
CY2021 xoma Increase Decrease In Refund Liability
IncreaseDecreaseInRefundLiability
-1305000
CY2020 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-4000
CY2020 xoma Increase Decrease In Refund Liability
IncreaseDecreaseInRefundLiability
612000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
2000000.0
CY2020 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
497000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
22678000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
10092000
CY2021 xoma Payments Related To Purchase Of Royalty Rights And Other Commercial Payment Rights
PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights
26500000
CY2020 xoma Payments Related To Purchase Of Royalty Rights And Other Commercial Payment Rights
PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights
1200000
CY2020 xoma Proceeds Related To Purchase Of Royalty Rights
ProceedsRelatedToPurchaseOfRoyaltyRights
1000000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-26500000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-209000
CY2021 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
40000000
CY2020 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
24600000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3385000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1945000
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1584000
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
4850000
CY2021 xoma Repayments Of Long Term Debt Excluding Extinguishment Of Debt
RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt
4250000
CY2020 xoma Repayments Of Long Term Debt Excluding Extinguishment Of Debt
RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt
5313000
CY2021 xoma Repayments Of Long Term Debt Extinguishment Of Debt
RepaymentsOfLongTermDebtExtinguishmentOfDebt
17103000
CY2021 us-gaap Payments Of Dividends
PaymentsOfDividends
3499000
CY2021 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
488000
CY2020 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2395000
CY2021 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-24000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12835000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19793000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9013000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
29676000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86364000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56688000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
95377000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86364000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
311000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
692000
CY2021 xoma Estimated Fair Value Of Contingent Consideration Under Purchase Agreements
EstimatedFairValueOfContingentConsiderationUnderPurchaseAgreements
8000000
CY2021Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
1368000
CY2020 xoma Interest Added Principal Balances Long Term Debt
InterestAddedPrincipalBalancesLongTermDebt
490000
CY2020 xoma Accrued Cost Related To Issuance Of Common Stock
AccruedCostRelatedToIssuanceOfCommonStock
264000
CY2021 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Description of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">XOMA (referred to as “XOMA” or the “Company”), a Delaware corporation, is a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered pre-commercial therapeutic candidates. The Company’s portfolio was built through licensing its proprietary products and platforms from its legacy discovery and development business, combined with the acquisition of rights to future milestones and royalties that the Company has made since the royalty aggregator business model was implemented in 2017. The Company’s drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase 1 and 2 with significant commercial sales potential that are licensed to large-cap partners. The Company expects that most of its future revenue will be based on payments the Company may receive for milestones and royalties related to these programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Liquidity and Financial Condition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred significant operating losses and negative cash flows from operations since its inception. As of December 31, 2021, the Company had unrestricted and restricted cash of $93.3 million and $2.0 million, respectively. The restricted cash balance may only be used to pay dividends on the outstanding Series A Preferred Stock and the outstanding Series B Preferred Stock (Note 12).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2021, the Company repaid its outstanding debt obligations to SVB and Novartis, for a total of $17.1 million (Note 8). Based on the Company’s current cash balance and its ability to control discretionary spending, such as royalty acquisitions, the Company has evaluated and concluded its financial condition is sufficient to fund its planned operations and commitments and contractual obligations for a period of at least one year following the date that these consolidated financial statements are issued.</p>
CY2021Q4 us-gaap Cash
Cash
93300000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
2142000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
95377000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86364000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under units-of-revenue method, royalty receivables, equity securities, legal contingencies, contingent consideration and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Actual results may differ significantly from these estimates, such as the Company’s billing under government contracts and amortization of the payments received from HCRP. Under the Company’s contracts with the NIAID, a part of the NIH, the Company billed using NIH’s provisional rates and thus is subject to future audits at the discretion of NIAID’s contracting office. In October of 2019, NIH notified the Company that it engaged KPMG to perform an audit of the Company’s incurred cost submissions for 2013, 2014 and 2015. As of December 31, 2020, the audit procedures were completed, and the Company adjusted its estimated liability owed to NIH to $1.4 million. In December 2021, the NIH </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">completed its review of the audit as part of the related contract close-out process, which included the finalization of rates for years 2010 through 2015, and the Company adjusted its liability owed to NIH to $1.3 million. In December 2021, the Company paid the final approved refund liability of $1.3 million. As such, no contingent liability remained on the Company’s consolidated balance sheets as of December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The COVID-19 pandemic has resulted in a global slowdown of economic activity which has led to delays and could result in further delays or terminations of some clinical trials underlying the Company’s RPAs. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. These estimates may change, as new events occur and additional information is obtained, and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s financial statements.</p>
CY2020Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
1400000
CY2021Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
1300000
CY2021Q4 xoma Increase Decrease In Refund Liability
IncreaseDecreaseInRefundLiability
-1300000
CY2021Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
0
CY2021Q4 us-gaap Cash
Cash
93328000
CY2020Q4 us-gaap Cash
Cash
84222000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
2049000
CY2021 xoma Impairment Of Long Term Royalty Receivable
ImpairmentOfLongTermRoyaltyReceivable
0
CY2020 xoma Impairment Of Long Term Royalty Receivable
ImpairmentOfLongTermRoyaltyReceivable
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021 us-gaap Reclassifications
Reclassifications
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;">Prior Period Reclassifications</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Within the consolidated statement of cash flows, the Company presented principal payments on its finance lease and proceeds from disgorgement of stockholder's short-swing profits together in order for the prior period to conform with current period presentation. </p>
CY2021 us-gaap Dividends
Dividends
0
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
295000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
351000
CY2021Q4 xoma Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
135000
CY2020Q4 xoma Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
136000
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
55000
CY2020Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
71000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
40000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
84000
CY2021Q4 xoma Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
525000
CY2020Q4 xoma Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
642000
CY2019Q4 xoma Long Term Rights Receivable Non Current
LongTermRightsReceivableNonCurrent
34375000
CY2020Q4 xoma Long Term Rights Receivable Non Current
LongTermRightsReceivableNonCurrent
34575000
CY2021Q4 xoma Long Term Rights Receivable Non Current
LongTermRightsReceivableNonCurrent
69075000
CY2020Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021 us-gaap Lease Cost
LeaseCost
185000
CY2020 us-gaap Lease Cost
LeaseCost
184000
CY2019Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
681000
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
1012000
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
1693000
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
617000
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
2310000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
202000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
34000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
236000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
229000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
177000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
177000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
8000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
7000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
196000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
189000
CY2021 xoma Effective Income Tax Rate Reconciliation Stock Compensation And Other Permanent Differences Percent
EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent
0.09
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y2M1D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y2M1D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0551
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0551
CY2021 us-gaap Interest Expense Debt
InterestExpenseDebt
461000
CY2020 us-gaap Interest Expense Debt
InterestExpenseDebt
1844000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
15900000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
11800000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1500000
CY2021 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
91000
CY2020 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-1501000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
91000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1501000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 xoma Effective Income Tax Rate Reconciliation Stock Compensation And Other Permanent Differences Percent
EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent
-0.06
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0
CY2021 xoma Effective Income Tax Rate Reconciliation Orphan Drug Credit Percent
EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent
0.02
CY2020 xoma Effective Income Tax Rate Reconciliation Tax Benefit Coronavirus Aid Relief And Economic Security Act Percent
EffectiveIncomeTaxRateReconciliationTaxBenefitCoronavirusAidReliefAndEconomicSecurityActPercent
-0.13
CY2021 xoma Effective Income Tax Rate Reconciliation Tax Expense Benefit Net Operating Loss Carryforward Utilization Percent
EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent
-0.11
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.16
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.15
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.01
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.13
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2020 xoma Income Tax Benefit Operating Loss Carry Back Coronavirus Aid Relief And Economic Security Act
IncomeTaxBenefitOperatingLossCarryBackCoronavirusAidReliefAndEconomicSecurityAct
1500000
CY2021 xoma Income Taxes Receivable Net Operating Loss Cares Act Cash Received
IncomeTaxesReceivableNetOperatingLossCaresActCashReceived
1500000
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
7822000
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
11500000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
17657000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
17638000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
13125000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
13454000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4778000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5158000
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
2817000
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
3462000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
807000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
401000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
47006000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
51613000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
47006000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
51613000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-4600000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-3900000
CY2021 xoma Operating Loss Carryforwards Offset Of Taxable Income Percentage
OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage
0.80
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5938000
CY2020 xoma Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
421000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5517000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.78
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.66
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5938000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5938000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5900000
CY2021Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2021Q4 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.50
CY2020 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.50
CY2020 xoma Defined Contribution Plan Age Required For Catch Up Contribution Minimum
DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum
P50Y
CY2021 xoma Defined Contribution Plan Age Required For Catch Up Contribution Minimum
DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum
P50Y
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
CY2021 xoma Defined Contribution Plan Cost Recognized And Paid Through Issuance Of Common Shares Percentage
DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage
1
CY2020 xoma Defined Contribution Plan Cost Recognized And Paid Through Issuance Of Common Shares Percentage
DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage
1
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1911177
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1827906
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y3M21D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
51401000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
325211
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
32.02
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
77305
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
13.61
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
164635
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
46.59
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1911177
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.64
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y3M29D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15103000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1553696
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
18.75
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y8M8D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
14894000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1600000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5400000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
22.23
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
18.41
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4100000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6195000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3961000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
479000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
622000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
15798000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
13298000
CY2021 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
3451000
CY2020 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
4417000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
7787000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
8793000
CY2021 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
-181000
CY2020 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
-217000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
7968000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
9010000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11288000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10674000
CY2021 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
900000
CY2020 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
824000
CY2021 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
4000
CY2020 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
5000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12192000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11503000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.69
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.82
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
11177
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
19426
CY2021Q4 xoma Contractual Obligation Estimated Milestone Payments
ContractualObligationEstimatedMilestonePayments
6300000
CY2021Q4 xoma Contractual Obligation Estimated Milestone Payments Number Of Products
ContractualObligationEstimatedMilestonePaymentsNumberOfProducts
1
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Revenues
Revenues
38160000
CY2020 us-gaap Revenues
Revenues
29385000

Files In Submission

Name View Source Status
0001558370-22-003022-index-headers.html Edgar Link pending
0001558370-22-003022-index.html Edgar Link pending
0001558370-22-003022.txt Edgar Link pending
0001558370-22-003022-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
R92.htm Edgar Link pending
R93.htm Edgar Link pending
R94.htm Edgar Link pending
R95.htm Edgar Link pending
R96.htm Edgar Link pending
R97.htm Edgar Link pending
R98.htm Edgar Link pending
R99.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20211231.xsd Edgar Link pending
tmb-20211231x10k.htm Edgar Link pending
tmb-20211231x10k_htm.xml Edgar Link completed
tmb-20211231xex10d26.htm Edgar Link pending
tmb-20211231xex10d26002.jpg Edgar Link pending
tmb-20211231xex10d48.htm Edgar Link pending
tmb-20211231xex21d1.htm Edgar Link pending
tmb-20211231xex23d1.htm Edgar Link pending
tmb-20211231xex31d1.htm Edgar Link pending
tmb-20211231xex31d2.htm Edgar Link pending
tmb-20211231xex32d1.htm Edgar Link pending
tmb-20211231xex4d6.htm Edgar Link pending
tmb-20211231_cal.xml Edgar Link unprocessable
tmb-20211231_def.xml Edgar Link unprocessable
tmb-20211231_lab.xml Edgar Link unprocessable
tmb-20211231_pre.xml Edgar Link unprocessable